MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,590.00
-75.00 (-1.61%)
Sep 19, 2025, 3:30 PM KST
-1.61%
Market Cap157.32B
Revenue (ttm)1.27B
Net Income (ttm)-11.80B
Shares Out34.28M
EPS (ttm)-346.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume340,037
Average Volume611,978
Open4,700.00
Previous Close4,665.00
Day's Range4,545.00 - 4,815.00
52-Week Range2,750.00 - 6,620.00
Beta0.62
RSI47.64
Earnings DateNov 11, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Employees 56
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.